Calliditas: Vera Therapeutics has released interesting additional 2b results - Redeye

Vera has a BAFF/APRIL B-Cell modulator based IgAN candidate called Atacicept, which has delivered 2b results and is in the early stage of a pivotal phase 3 study ORIGIN 3. This candidate could eventually offer a clinical filtration benefit for IgAN patients like Tarpeyo.

Länk till analysen i sin helhet: https://www.redeye.se/research/972489/calliditas-vera-therapeutics-has-released-interesting-additional-2b-results?utm_source=finwire&utm_medium=RSS